Login to Your Account

Abbvie Starts Its Second Phase III of Neurocrine’s Elagolix

By Marie Powers
Staff Writer

Friday, August 30, 2013
Abbvie Inc. launched the second pivotal Phase III trial of elagolix in endometriosis, moving Neurocrine Biosciences Inc. one step closer to key catalysts for its product development pipeline. The 24-week, multinational, randomized, double-blind, placebo-controlled study is almost identical in design to the initial Phase III, with both evaluating safety and efficacy in premenopausal women with moderate to severe pain associated with endometriosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription